GO:0044027 negative regulation of gene expression via chromosomal CpG island methylation: Epigenetic Silencing, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0044027 describes an epigenetic mechanism that silences gene expression by adding methyl groups to cytosine residues within CpG islands, which are CG-rich regions near transcription start sites.
• DNA methylation patterns are highly variable between individuals and are associated with changes in gene expression, making this process a key source of inter-individual phenotypic variation.
• Aberrant CpG island hypermethylation is a hallmark of many cancers, where it can silence tumor suppressor genes and other cancer-associated genes.
• Environmental and nutritional factors, such as folic acid availability, can influence promoter methylation and subsequent mRNA expression.
• Studying this process requires integrating genome-wide methylation data with transcriptomic and epigenomic profiling to link methylation events to gene silencing.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal testing of candidate genes involved in CpG island methylation and its downstream effects.
Description
GO:0044027, negative regulation of gene expression via chromosomal CpG island methylation, is a biological process that represses transcription through the addition of methyl groups to cytosine residues in CpG islands, which are genomic regions rich in CG dinucleotides and frequently located near transcription start sites. This epigenetic modification does not alter the DNA sequence but provides a stable, heritable mark that can be propagated through cell divisions, thereby contributing to long-term gene silencing. Because CpG islands often overlap with promoters of housekeeping and developmental genes, their methylation status is a critical determinant of normal cellular identity and function. Dysregulation of this process is widely implicated in human disease. For example, genome-wide DNA methylation profiling in Hashimoto thyroiditis has revealed altered methylation patterns in whole blood, suggesting a role for epigenetic silencing in autoimmune thyroid disease. In multiple myeloma, analysis of methylation patterns has provided insights into the epigenetic landscape of the disease. In breast and ovarian cancers, promoter methylation of cancer-associated genes such as those on chromosome 3p, along with changes in their predicted regulator microRNAs, has been documented. These findings underscore the importance of understanding how CpG island methylation is targeted, maintained, and how it can be reversed or modeled experimentally. For researchers, GO:0044027 represents a convergence point for epigenetics, transcription regulation, and disease biology. Investigating this process requires tools that can quantify DNA methylation at single-base resolution, link methylation to gene expression changes, and manipulate candidate regulators. This article provides a research-grade overview of the definition, mechanism, key genes, disease relevance, and experimental strategies, including CRISPR-based models, for studying negative regulation of gene expression via chromosomal CpG island methylation.
negative regulation of gene expression via chromosomal CpG island methylation At A Glance
| GO ID | GO:0044027 |
|---|---|
| GO term | negative regulation of gene expression via chromosomal CpG island methylation |
| Ontology | biological_process |
| Synonym | DNA hypermethylation of CpG island; epigenetic regulation of gene expression via CpG island hypermethylation; maintenance of DNA methylation; negative regulation of gene expression via CpG island methylation |
| Major function | Epigenetic silencing of gene expression through methylation of cytosine residues in CpG islands, often near transcription start sites |
| Related process | DNA methylation, gene silencing, chromatin remodeling, transcriptional repression |
| Cellular context | Nuclear chromatin; CpG islands are genomic regions with high CG dinucleotide frequency |
| Disease relevance | Cancer, autoimmune conditions such as Hashimoto thyroiditis, and other diseases with aberrant methylation |
What Is GO:0044027?
GO:0044027 is defined as an epigenetic gene regulation mechanism that negatively regulates gene expression by methylation of cytosine residues in chromosomal CpG islands. CpG islands are genomic regions that contain a high frequency of the CG dinucleotide and are often associated with the transcription start site of genes. In essence, when cytosines within these islands become methylated, the associated gene is typically silenced or repressed, and this process is a key component of epigenetic control.
Why Is negative regulation of gene expression via chromosomal CpG island methylation Important in Cell Biology?
GO:0044027 is critically important because CpG island methylation is a major epigenetic mechanism for stable gene silencing, and its dysregulation contributes to a wide range of human diseases. In cancer, hypermethylation of CpG islands can silence tumor suppressor genes, thereby promoting tumorigenesis. In autoimmune diseases such as Hashimoto thyroiditis, altered DNA methylation patterns in whole blood suggest that epigenetic silencing may contribute to disease pathogenesis. In hematological malignancies like multiple myeloma, methylation patterns provide insights into disease biology and potential therapeutic targets. Furthermore, inter-individual variation in DNA methylation is associated with differences in gene expression, highlighting its role in normal human phenotypic diversity. Understanding this process is therefore essential for basic biology, biomarker discovery, and the development of epigenetic therapies.
• Provides a stable, heritable mechanism for long-term gene silencing without changing the DNA sequence.
• Contributes to inter-individual variation in gene expression and phenotypic diversity.
• Is frequently dysregulated in cancer, where CpG island hypermethylation silences tumor suppressor genes.
• Has been implicated in autoimmune diseases such as Hashimoto thyroiditis through altered blood methylation patterns.
• Is relevant to hematological malignancies like multiple myeloma, where methylation patterns are altered.
• Can be influenced by environmental factors such as folate availability, linking nutrition to epigenetic regulation.
• Serves as a target for epigenetic drugs (e.g., DNA methyltransferase inhibitors) in cancer therapy.
• Requires integration of methylation and expression data to identify functionally relevant silencing events.
• Can be studied using CRISPR-based models to test causality of candidate regulators.
• Is a key consideration in stem cell biology, development, and cellular reprogramming.
What Happens During negative regulation of gene expression via chromosomal CpG island methylation?
Establishment of CpG island methylation
In simple terms: This is the step where methyl groups are first added to cytosines in a CpG island.
The establishment of CpG island methylation involves the addition of a methyl group to the 5-carbon position of cytosine, typically within a CG dinucleotide context. This process is mediated by DNA methyltransferases (DNMTs), which can be recruited to specific genomic regions by various factors, including transcription factors, chromatin modifiers, and non-coding RNAs. In the context of GO:0044027, this methylation occurs in CpG islands, which are CG-rich regions often overlapping with gene promoters. The initial targeting of DNMTs to specific CpG islands is a key regulatory step and can be influenced by environmental factors such as folate availability.
Maintenance of methylation through cell division
In simple terms: Once methyl marks are placed, they are copied to new DNA strands during cell division so the gene stays off.
After establishment, CpG island methylation patterns are maintained through DNA replication by maintenance DNA methyltransferases, which recognize hemimethylated DNA and restore full methylation on the newly synthesized strand. This ensures that the silenced state is heritable across cell generations. The QuickGO synonym 'maintenance of DNA methylation' reflects this critical aspect of the process. Maintenance methylation is essential for stable epigenetic silencing and is a hallmark of GO:0044027.
Recognition of methylated CpG islands by methyl-CpG-binding proteins
In simple terms: Proteins that specifically bind to methylated DNA recognize the marks and help turn the gene off.
Methylated CpG islands are bound by methyl-CpG-binding domain (MBD) proteins, such as MeCP2, MBD1, MBD2, and MBD4, as well as other proteins like Kaiso. These proteins recruit co-repressor complexes containing histone deacetylases (HDACs) and histone methyltransferases, leading to chromatin compaction and transcriptional repression. This step links DNA methylation to changes in chromatin structure, reinforcing gene silencing. The interplay between DNA methylation and histone modifications is a key feature of negative regulation of gene expression via CpG island methylation.
Transcriptional repression and gene silencing
In simple terms: The ultimate outcome is that the gene is turned off or its expression is strongly reduced.
The combination of methylated CpG islands, methyl-CpG-binding proteins, and repressive chromatin modifications leads to reduced accessibility of the promoter to the transcription machinery. This results in decreased transcription initiation and, consequently, lower mRNA and protein levels. In some cases, methylation may also interfere directly with the binding of transcription factors to their cognate sites. The functional consequence is negative regulation of gene expression, as defined for GO:0044027. This silencing can be stable and may persist through multiple cell divisions, contributing to cellular memory and identity.
Dynamics and reversibility of CpG island methylation
In simple terms: Methyl marks can be removed or altered, allowing genes to be turned back on under certain conditions.
Although CpG island methylation is often stable, it is not irreversible. Active DNA demethylation can occur through the action of ten-eleven translocation (TET) enzymes, which oxidize 5-methylcytosine to 5-hydroxymethylcytosine and further derivatives, ultimately leading to demethylation. This dynamic nature allows for changes in gene expression in response to developmental cues, environmental signals, or pharmacological interventions. The reversibility of methylation is exploited in cancer therapy with DNA methyltransferase inhibitors. Understanding the balance between methylation and demethylation is essential for a complete picture of GO:0044027.
Key Genes Involved in GO:0044027 negative regulation of gene expression via chromosomal CpG island methylation
The following genes and proteins are central to the establishment, maintenance, recognition, and functional consequences of CpG island methylation as described in GO:0044027.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DNMT1 | Maintenance DNA methyltransferase; copies methylation patterns during replication | Target for epigenetic therapy; knockout models show global hypomethylation |
| DNMT3A | De novo DNA methyltransferase; establishes new methylation marks | Frequently mutated in hematological malignancies; knockout affects development |
| DNMT3B | De novo DNA methyltransferase; establishes new methylation marks | Mutations cause immunodeficiency-centromeric instability-facial anomalies syndrome |
| TET1 | Catalyzes oxidation of 5-methylcytosine, initiating demethylation | Knockout alters methylation dynamics and gene expression |
| TET2 | Catalyzes oxidation of 5-methylcytosine; involved in demethylation | Mutated in myeloid malignancies; knockout models show aberrant methylation |
| MBD1 | Binds methylated CpG and recruits repressive complexes | Knockout affects gene silencing and chromatin structure |
| MBD2 | Binds methylated DNA and recruits HDAC complexes | Knockout leads to demethylation-independent gene activation |
| MECP2 | Binds methylated CpG and mediates transcriptional repression | Mutations cause Rett syndrome; knockout models show neurological defects |
| EZH2 | Histone methyltransferase that interacts with DNA methylation machinery | Overexpressed in cancers; can regulate gene expression via miRNA |
| XIAP | Anti-apoptotic protein whose expression can be influenced by methylation-related pathways | Regulated by EZH2/miRNA-219 axis in CML cells |
| ARSD | ERα downstream target gene; its expression may be affected by promoter methylation | Inhibits proliferation and migration in breast cancer cells |
| ESR1 | Estrogen receptor alpha; its target genes can be epigenetically regulated | Relevant to breast cancer; downstream targets like ARSD affect Hippo/YAP pathway |
| miR-129-2 | MicroRNA predicted to regulate cancer-associated 3p genes | Methylation of its promoter may affect target gene expression in breast/ovarian cancers |
| miR-9-1 | MicroRNA predicted to regulate cancer-associated 3p genes | Methylation of its promoter may affect target gene expression in breast/ovarian cancers |
| Folate-related genes | Influence one-carbon metabolism and methyl donor availability | Folic acid affects promoter methylation and mRNA expression in chicken B cells |
| BCR/ABL | Fusion oncogene in chronic myeloid leukemia; affects epigenetic regulators | Increases EZH2 levels, which regulates XIAP via miRNA-219 |
| Global methylation markers | Indicative of genome-wide methylation status | Used in studies of multiple myeloma and Hashimoto thyroiditis |
How Is negative regulation of gene expression via chromosomal CpG island methylation Regulated?
The process of negative regulation of gene expression via chromosomal CpG island methylation is itself regulated at multiple levels. The targeting of DNA methyltransferases to specific CpG islands can be influenced by transcription factors, chromatin context, and non-coding RNAs. Environmental factors, such as folate availability, can affect the availability of methyl donors and thus impact promoter methylation and mRNA expression. In chronic myeloid leukemia cells, the BCR/ABL fusion protein increases EZH2 levels, which in turn regulates XIAP expression via miRNA-219, illustrating cross-talk between oncogenic signaling and epigenetic regulation. Additionally, the estrogen receptor alpha (ERα) pathway can influence the expression of downstream target genes such as ARSD, which may be subject to epigenetic regulation. These examples highlight that CpG island methylation is not an isolated process but is integrated with cellular signaling and transcriptional networks.
negative regulation of gene expression via chromosomal CpG island methylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DNMT3A | Hematological malignancies; altered de novo methylation | Knockout or point-mutation cell lines to study methylation changes |
| TET2 | Myeloid malignancies; impaired demethylation | Knockout models to assess methylation dynamics |
| MECP2 | Rett syndrome; defective methyl-CpG binding | Knock-in of patient mutations in neuronal cells |
| EZH2 | Chronic myeloid leukemia; regulates XIAP via miRNA-219 | Knockdown or overexpression in CML cell lines |
| ARSD | Breast cancer; ERα downstream target affecting Hippo/YAP | Overexpression or knockout in breast cancer cells |
Cancer
Aberrant CpG island hypermethylation is a common feature of many cancers, where it can lead to the silencing of tumor suppressor genes and other cancer-associated genes. In breast and ovarian cancers, promoter methylation of chromosome 3p genes and their predicted regulator microRNAs (miR-129-2, miR-9-1) has been observed, suggesting a role for epigenetic silencing in tumorigenesis. In chronic myeloid leukemia, the BCR/ABL fusion protein increases EZH2 levels, which regulates XIAP expression via miRNA-219, linking oncogenic signaling to epigenetic gene regulation. In multiple myeloma, analysis of methylation patterns has provided insights into the epigenetic landscape of the disease. These findings underscore the importance of CpG island methylation in cancer biology and its potential as a therapeutic target.
Autoimmune and endocrine disorders
Genome-wide DNA methylation profiling in whole blood of patients with Hashimoto thyroiditis has revealed altered methylation patterns, suggesting that epigenetic silencing via CpG island methylation may contribute to autoimmune thyroid disease pathogenesis. This highlights the broader relevance of GO:0044027 beyond cancer, extending to autoimmune and endocrine conditions.
Aging and cardiovascular biology
The biological age of the heart has been studied in relation to DNA methylation, with evidence that the heart's biological age is consistently younger than its chronological age. This suggests that CpG island methylation patterns may serve as biomarkers of aging and have implications for cardiovascular health. While the exact mechanisms remain under investigation, these findings link epigenetic regulation to aging processes.
Nutritional and environmental influences
Environmental and nutritional factors can influence CpG island methylation. For example, folic acid supplementation has been shown to affect the methylation status of gene proximal promoter areas and mRNA expression in chicken B cells, indicating a direct link between nutrition and epigenetic regulation. This underscores the potential for dietary interventions to modulate GO:0044027-related processes.
From negative regulation of gene expression via chromosomal CpG island methylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DNMT1 lead to demethylation of specific CpG islands? | DNMT1 knockout cell line (e.g., HCT116) |
| Does a point mutation in DNMT3A affect its methyltransferase activity? | Point-mutation knock-in via CRISPR in cell lines |
| Can we tag endogenous MECP2 to study its binding dynamics? | Knock-in of fluorescent or epitope tags at the MECP2 locus |
| Does overexpression of EZH2 alter XIAP expression via miRNA-219? | EZH2 overexpression in CML cell lines |
| Does ARSD overexpression affect proliferation and migration in breast cancer? | ARSD overexpression in breast cancer cell lines |
| Does folate deficiency alter promoter methylation of immune genes? | Dietary manipulation in chicken B cell models |
How to Study the negative regulation of gene expression via chromosomal CpG island methylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Whole-genome bisulfite sequencing (WGBS) | DNA methylation at single-base resolution | Global methylome profiling in disease vs. normal tissues |
| Illumina methylation array | Methylation levels at specific CpG sites | Large-scale epigenome-wide association studies |
| RNA-seq | Gene expression levels | Correlating methylation with transcriptional silencing |
| ChIP-seq | Protein-DNA interactions | Mapping DNMT and MBD binding sites |
| MeDIP-seq | Enrichment of methylated DNA | Identifying methylated regions without bisulfite conversion |
| CRISPR knockout | Loss of gene function | Testing causal role of candidate genes |
| CRISPR knock-in | Introduction of specific mutations or tags | Modeling patient mutations or tagging endogenous proteins |
| CRISPR library screening | Phenotypic effects of many gene perturbations | Identifying novel regulators of CpG island methylation |
Genome-wide methylation profiling
Techniques such as whole-genome bisulfite sequencing (WGBS) and Illumina methylation arrays allow for single-base resolution mapping of DNA methylation across the genome. These methods are essential for identifying differentially methylated regions, including CpG islands, and for linking methylation changes to gene expression. Studies in Hashimoto thyroiditis and multiple myeloma have utilized such approaches to characterize disease-associated methylation patterns.
Transcriptomic analysis
RNA sequencing (RNA-seq) and quantitative PCR are used to measure gene expression levels and correlate them with methylation status. By integrating methylome and transcriptome data, researchers can identify genes whose silencing is likely driven by CpG island hypermethylation. This approach has been applied in breast and ovarian cancers to study the relationship between promoter methylation and expression of 3p genes and their regulator microRNAs.
Epigenetic editing and CRISPR screening
CRISPR-based tools, such as CRISPRi and CRISPRa, can be used to manipulate gene expression without altering the DNA sequence, while CRISPR knockout, knock-in, and point mutations enable causal testing of specific genes. Library screening with CRISPR can identify regulators of CpG island methylation. These methods are powerful for dissecting the molecular players in GO:0044027.
Protein-DNA interaction assays
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) and methylated DNA immunoprecipitation (MeDIP) are used to study the binding of proteins such as DNMTs and MBDs to methylated CpG islands. These assays help elucidate the recruitment and maintenance mechanisms of methylation. They are complemented by bisulfite sequencing to confirm methylation status.
How CRISPR Can Be Used to Study GO:0044027 negative regulation of gene expression via chromosomal CpG island methylation
Knockout
CRISPR knockout is used to create cell lines with loss-of-function mutations in genes involved in CpG island methylation, such as DNMT1, DNMT3A, DNMT3B, TET1, TET2, MBD1, MBD2, and MECP2. These models allow researchers to study the consequences of gene loss on global and locus-specific methylation, gene expression, and cellular phenotypes. For example, DNMT1 knockout leads to passive demethylation and reactivation of silenced genes.
Point Mutation
CRISPR point mutation (base editing or homology-directed repair) enables the introduction of specific disease-associated mutations into genes like DNMT3A or MECP2. This is particularly useful for modeling missense mutations that alter enzymatic activity or DNA binding without completely abolishing protein expression. Such models help dissect the functional impact of individual mutations on CpG island methylation and gene silencing.
Knock-in
CRISPR knock-in can be used to insert reporter genes, epitope tags, or loxP sites into endogenous loci. For example, tagging endogenous MECP2 with a fluorescent protein allows real-time tracking of its binding to methylated CpG islands. Knock-in of patient-specific mutations into the endogenous locus provides a more physiologically relevant model than overexpression.
Overexpression
CRISPR activation (CRISPRa) or traditional cDNA overexpression can be used to increase the levels of genes such as EZH2 or ARSD to study their effects on CpG island methylation and downstream gene expression. Overexpression of EZH2 in chronic myeloid leukemia cells has been shown to regulate XIAP expression via miRNA-219, illustrating the utility of this approach. Similarly, ARSD overexpression in breast cancer cells inhibits proliferation and migration via the Hippo/YAP pathway.
How EDITGENE Supports negative regulation of gene expression via chromosomal CpG island methylation Research
Researchers studying negative regulation of gene expression via chromosomal CpG island methylation-related genes often need to determine whether a candidate gene is causally involved in the process or is merely correlated with methylation changes. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal investigations, from generating knockout cell lines to performing genome-wide library screens.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of gene expression via chromosomal CpG island methylation research.
Frequently Asked Questions About negative regulation of gene expression via chromosomal CpG island methylation
What is GO:0044027?
GO:0044027 is a Gene Ontology biological process term that describes negative regulation of gene expression via chromosomal CpG island methylation. It refers to the epigenetic silencing of genes through the addition of methyl groups to cytosine residues in CpG islands, which are CG-rich regions often near transcription start sites.
What genes are involved in negative regulation of gene expression via chromosomal CpG island methylation?
Key genes include DNA methyltransferases (DNMT1, DNMT3A, DNMT3B), ten-eleven translocation enzymes (TET1, TET2), methyl-CpG-binding proteins (MBD1, MBD2, MECP2), and chromatin modifiers such as EZH2. Other genes like ARSD and ESR1 can be downstream targets or regulators in specific contexts.
How does CpG island methylation silence genes?
Methylation of cytosines in CpG islands recruits methyl-CpG-binding proteins, which in turn recruit co-repressor complexes containing histone deacetylases and histone methyltransferases. This leads to chromatin compaction and reduced accessibility of the promoter to transcription factors, resulting in transcriptional repression.
What diseases are associated with abnormal CpG island methylation?
Aberrant CpG island methylation is associated with many cancers, including breast, ovarian, and hematological malignancies, as well as autoimmune diseases like Hashimoto thyroiditis, and aging-related conditions.
How can CRISPR be used to study CpG island methylation?
CRISPR can be used to create knockout, point mutation, knock-in, and overexpression models of genes involved in CpG island methylation. These models allow researchers to test the causal role of specific genes and mutations in methylation and gene silencing.
What methods are used to measure DNA methylation?
Common methods include whole-genome bisulfite sequencing (WGBS), Illumina methylation arrays, methylated DNA immunoprecipitation (MeDIP), and bisulfite pyrosequencing. These techniques quantify methylation at single-base or regional resolution.
Can environmental factors affect CpG island methylation?
Yes, nutritional factors such as folate availability can influence the availability of methyl donors and thereby affect promoter methylation and gene expression, as shown in studies on chicken B cells.
What is the role of TET enzymes in CpG island methylation?
TET enzymes catalyze the oxidation of 5-methylcytosine, initiating active DNA demethylation. They counteract methylation-mediated silencing and are important for dynamic regulation of gene expression.
How does EZH2 regulate gene expression in chronic myeloid leukemia?
In chronic myeloid leukemia cells, BCR/ABL increases EZH2 levels, which regulates XIAP expression via miRNA-219. This illustrates cross-talk between oncogenic signaling and epigenetic regulation.
What are the potential therapeutic implications of targeting CpG island methylation?
DNA methyltransferase inhibitors (e.g., azacitidine, decitabine) are used in cancer therapy to reverse aberrant methylation and reactivate silenced tumor suppressor genes. Understanding GO:0044027 can guide the development of more targeted epigenetic therapies.
Conclusion
GO:0044027, negative regulation of gene expression via chromosomal CpG island methylation, is a fundamental epigenetic process that controls gene silencing through the addition of methyl marks to CpG-rich regions. Its dysregulation is implicated in cancer, autoimmune diseases, and aging, making it a critical area of biomedical research. Advances in methylation profiling, transcriptomics, and CRISPR-based modeling are enabling researchers to dissect the causal roles of specific genes and mutations in this process. EDITGENE's comprehensive services support these efforts by providing custom knockout, point mutation, knock-in, overexpression, and screening models, along with expert bioinformatics analysis.
References
- 1. San-Miguel J et al.. 2005. Analysis of methylation pattern in multiple myeloma.. Acta Haematol 114 Suppl 1:23-6 PMID: 16166769
- 2. Zhou Z et al.. 2023. Genome-wide DNA methylation pattern in whole blood of patients with Hashimoto thyroiditis.. Front Endocrinol (Lausanne) 14:1259903 PMID: 38075038
- 3. Wagner JR et al.. 2014. The relationship between DNA methylation, genetic and expression inter-individual variation in untransformed human fibroblasts.. Genome Biol 15(2):R37 PMID: 24555846
- 4. Pronina IV et al.. 2016. Expression and DNA methylation alterations of seven cancer-associated 3p genes and their predicted regulator miRNAs (miR-129-2, miR-9-1) in breast and ovarian cancers.. Gene 576(1 Pt 3):483-91 PMID: 26519551
- 5. Nishioka C et al.. 2016. BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells.. Leuk Res 45:24-32 PMID: 27070757
- 6. Elad O et al.. 2020. Epigenetic effect of folic acid (FA) on the gene proximal promoter area and mRNA expression of chicken B cell as antigen presenting cells.. Br Poult Sci 61(6):725-733 PMID: 32705890
- 7. Lin Y et al.. 2021. ARSD, a novel ERα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo/YAP pathway.. Cell Death Dis 12(11):1042 PMID: 34725332
- 8. Pavanello S et al.. 2020. The biological age of the heart is consistently younger than chronological age.. Sci Rep 10(1):10752 PMID: 32612244
